Russell Investments Group
NVCT icon

Russell Investments Group’s Nuvectis Pharma NVCT Stock Holding History

Russell Investments Group’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.24K Hold
1,066
– – ﹤0.01% 3820
2025
Q4 		$8.05K Hold
1,066
– – ﹤0.01% 3841
2025
Q3 		$6.42K Buy
+1,066
New +$7.33K ﹤0.01% 3860

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Russell Investments Group's NVCT Position: Q1 2026 in Review

Russell Investments Group held its Nuvectis Pharma (NVCT) position steady in Q1 2026 at 1,066 shares worth $8.24K. The position accounts for ﹤0.01% of the portfolio, ranked #3820.

Russell Investments Group first reported a position in NVCT in Q3 2025 and has held it in 3 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Russell Investments Group held 1,066 shares of Nuvectis Pharma worth $8.24K as of Q1 2026.
  • Russell Investments Group left its Nuvectis Pharma share count unchanged in Q1 2026.
  • Nuvectis Pharma made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3820 holding.
  • Russell Investments Group first reported a position in Nuvectis Pharma in Q3 2025 and has held it in 3 quarters since.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.